Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRP2945 in drug-resistant absence epilepsy
ACTRN12618001506280Phase 2Completed
- Sponsor
- CuroNZ
- Start
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, single-blind trial of NRP2945 in absence epilepsy (3 arms), sponsored by CuroNZ. Primary endpoint: Safety and tolerability of NRP2945. Started Dec 2018; status: completed.
02
Drugs
NRP2945
03
Conditions
absence epilepsy
Beyond the preview
Go deeper on ACTRN12618001506280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001506280.